125 related articles for article (PubMed ID: 26416421)
1. Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival.
Kapetanakis NI; Uzan C; Jimenez-Pailhes AS; Gouy S; Bentivegna E; Morice P; Caron O; Gourzones-Dmitriev C; Le Teuff G; Busson P
Oncotarget; 2015 Nov; 6(34):36815-24. PubMed ID: 26416421
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Oncotarget; 2016 Mar; 7(13):16923-35. PubMed ID: 26943577
[TBL] [Abstract][Full Text] [Related]
3. Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Adv Exp Med Biol; 2016; 924():3-8. PubMed ID: 27753009
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Robelin P; Tod M; Colomban O; Lachuer J; Ray-Coquard I; Rauglaudre G; Joly F; Chevalier-Place A; Combe P; Lortholary A; Hamizi S; Raban N; Ferron G; Meunier J; Berton-Rigaud D; Alexandre J; Kaminsky MC; Dubot C; Leary A; Malaurie E; You B
Gynecol Oncol; 2020 Oct; 159(1):256-263. PubMed ID: 32712155
[TBL] [Abstract][Full Text] [Related]
5. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
Shah JS; Gard GB; Yang J; Maidens J; Valmadre S; Soon PS; Marsh DJ
Gynecol Oncol; 2018 Jan; 148(1):181-188. PubMed ID: 29132874
[TBL] [Abstract][Full Text] [Related]
6. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer.
Kan CW; Hahn MA; Gard GB; Maidens J; Huh JY; Marsh DJ; Howell VM
BMC Cancer; 2012 Dec; 12():627. PubMed ID: 23272653
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.
Meng X; Joosse SA; Müller V; Trillsch F; Milde-Langosch K; Mahner S; Geffken M; Pantel K; Schwarzenbach H
Br J Cancer; 2015 Nov; 113(9):1358-66. PubMed ID: 26393886
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
Halvorsen AR; Kristensen G; Embleton A; Adusei C; Barretina-Ginesta MP; Beale P; Helland Å
Dis Markers; 2017; 2017():3098542. PubMed ID: 28293063
[TBL] [Abstract][Full Text] [Related]
10. Low serum exosomal miR-484 expression predicts unfavorable prognosis in ovarian cancer.
Zhang W; Su X; Li S; Liu Z; Wang Q; Zeng H
Cancer Biomark; 2020; 27(4):485-491. PubMed ID: 32065786
[TBL] [Abstract][Full Text] [Related]
11. Serum microRNA-145 as a novel biomarker in human ovarian cancer.
Liang H; Jiang Z; Xie G; Lu Y
Tumour Biol; 2015 Jul; 36(7):5305-13. PubMed ID: 25722112
[TBL] [Abstract][Full Text] [Related]
12. Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer.
Choi PW; Bahrampour A; Ng SK; Liu SK; Qiu W; Xie F; Kuo WP; Kwong J; Hales KH; Hales DB; Wong KK; Norwitz ER; Chow CK; Berkowitz RS; Ng SW
Sci Rep; 2020 Nov; 10(1):20071. PubMed ID: 33208870
[TBL] [Abstract][Full Text] [Related]
13. Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.
Szajnik M; Czystowska-Kuźmicz M; Elishaev E; Whiteside TL
Expert Rev Mol Diagn; 2016 Aug; 16(8):811-26. PubMed ID: 27268121
[TBL] [Abstract][Full Text] [Related]
14. Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients.
Ji T; Zheng ZG; Wang FM; Xu LJ; Li LF; Cheng QH; Guo JF; Ding XF
Asian Pac J Cancer Prev; 2014; 15(4):1739-43. PubMed ID: 24641401
[TBL] [Abstract][Full Text] [Related]
15. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer.
Piatek S; Panek G; Lewandowski Z; Bidzinski M; Piatek D; Kosinski P; Wielgos M
J Ovarian Res; 2020 Sep; 13(1):102. PubMed ID: 32878632
[TBL] [Abstract][Full Text] [Related]
16. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.
Taylor DD; Gercel-Taylor C
Gynecol Oncol; 2008 Jul; 110(1):13-21. PubMed ID: 18589210
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
20. Exosomal microRNAs as tumor markers in epithelial ovarian cancer.
Pan C; Stevic I; Müller V; Ni Q; Oliveira-Ferrer L; Pantel K; Schwarzenbach H
Mol Oncol; 2018 Nov; 12(11):1935-1948. PubMed ID: 30107086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
